Salud financiera de hoja de balance de CSL

Salud financiera controles de criterios 5/6

CSL tiene un patrimonio de accionistas total de $21.4B y una deuda total de $9.8B, lo que sitúa su ratio deuda-patrimonio en 45.9%. Sus activos y pasivos totales son $39.4B y $18.0B respectivamente. El BAIT de CSL es de $4.1B, por lo que su ratio de cobertura de intereses es de 10.1. Tiene efectivo e inversiones a corto plazo que ascienden a $2.2B.

Información clave

45.95%

Ratio deuda-patrimonio

US$9.84b

Deuda

Ratio de cobertura de intereses	10.1x
Efectivo	US$2.16b
Patrimonio	US$21.41b
Total pasivo	US$18.00b
Activos totales	US$39.40b

Actualizaciones recientes sobre salud financiera

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

Jun 14

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

Recent updates

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price

Jan 10

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($11.9B) de CSL superan a sus pasivos a corto plazo ($4.8B).

Pasivo a largo plazo: Los activos a corto plazo ($11.9B) de CSL no cubren sus pasivos a largo plazo ($13.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (35.9%) de CSL se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de CSL ha pasado de 75.8% a 45.9% en los últimos 5 años.

Cobertura de la deuda: La deuda de CSL está bien cubierta por el flujo de caja operativo (36.2%).

Cobertura de intereses: Los pagos de intereses de la deuda de CSL están bien cubiertos por el BAIT (10.1x cobertura).

Hoja de balance

Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/10/04 01:43
Precio de las acciones al final del día	2025/10/03 00:00
Beneficios	2025/06/30
Ingresos anuales	2025/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

CSL Limited está cubierta por 28 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Saul Hadassin	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter
Lyanne Harrison	BofA Global Research

Salud financiera de hoja de balance de CSL

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Recent updates

CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up

CSL Limited, Annual General Meeting, Oct 28, 2025

Upcoming dividend of US$1.62 per share

Consensus EPS estimates fall by 22%

Investor sentiment deteriorates as stock falls 20%

CSL Limited to Report First Half, 2026 Results on Feb 02, 2026

High number of new directors

CSL Limited Announces Unfranked Dividend for the Period of Six Months Ended June 30, 2025, Payable on October 03, 2025

Final dividend of US$1.62 announced

CSL Limited Provides Earnings Guidance for the Year 2026

Full year 2025 earnings released: EPS: US$6.20 (vs US$5.47 in FY 2024)

Health Canada Authorized CSL's Andembry (Garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (Hae)

Is CSL Limited (ASX:CSL) Trading At A 43% Discount?

CSL Limited announces U.S. Food and Drug Administration Approves Csl's Andembry®? (Garadacimab-Gxii) Treatment Targeting Factor Xiia with Once-Monthly Dosing for All Patients from the Start

Here's Why CSL (ASX:CSL) Can Manage Its Debt Responsibly

CSL Vifor Announces England's Nice Recommends Filspari®? (Sparsentan) as A Treatment Option for IgA Nephropathy

Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog

CSL is undervalued in High Tax Scenario

Upcoming dividend of US$1.30 per share

Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position

CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine

European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)

First half dividend of US$1.30 announced

First half 2025 earnings: EPS and revenues miss analyst expectations

Joy Linton Resumes the Role of Chief Financial Officer of CSL Limited

CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Should You Be Adding CSL (ASX:CSL) To Your Watchlist Today?

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 43% Above Its Share Price

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio